Impact of HIV Type 1 Drug Resistance Mutations and Phenotypic Resistance Profile on Virologic Response to Salvage Therapy
- 10 October 2001
- journal article
- Published by Mary Ann Liebert Inc in AIDS Research and Human Retroviruses
- Vol. 17 (15) , 1379-1385
- https://doi.org/10.1089/088922201753197042
Abstract
This study examines the association between presence of drug resistance mutations and phenotypic resistance at baseline to virologic response to salvage therapy in a community setting. The study population consisted of 58 antiretroviral drug-experienced patients with HIV-1 infection who had recently switched therapy because of virologic failure. Drug resistance mutations in the reverse transcriptase- and protease-coding regions and phenotypic susceptibility to 13 antiretroviral drugs were assessed at baseline. Plasma HIV-1 RNA levels were assessed at baseline and at subsequent clinic visits. Results showed that three variables were significant in predicting virologic response: HIV-1 levels at baseline, number of protease mutations, and phenotypic sensitivity score for the regimen at baseline. For four drugs there was a significant association between the presence of specific drug resistance mutations and >10-fold phenotypic resistance to that drug. With phenotypic resistance defined as >4-fold resistance, the association between specific drug resistance mutations and phenotypic resistance was significant for seven drugs. Overall, these data show that phenotypic susceptibility and absence of drug resistance mutations, particularly protease mutations, are significant predictors of virologic response. For several drugs, specific combinations of drug resistance mutations are associated with decreased phenotypic susceptibility and might provide useful clinical guidelines in selecting therapeutic options.Keywords
This publication has 26 references indexed in Scilit:
- Reduced Susceptibility of Human Immunodeficiency Virus Type 1 (HIV-1) from Patients with Primary HIV Infection to Nonnucleoside Reverse Transcriptase Inhibitors Is Associated with Variation at Novel Amino Acid SitesJournal of Virology, 2000
- A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapyAIDS, 2000
- Human Immunodeficiency Virus–Infected Persons with Mutations Conferring Resistance to Zidovudine Show Reduced Virologic Responses to Hydroxyurea and Stavudine‐LamivudineThe Journal of Infectious Diseases, 2000
- Mutations conferring resistance to zidovudine diminish the antiviral effect of stavudine plus didanosineJournal of Medical Virology, 1999
- Emergence of zidovudine and multidrug-resistance mutations in the HIV-1 reverse transcriptase gene in therapy-naive patients receiving stavudine plus didanosine combination therapyAIDS, 1999
- Clinical Resistance Patterns and Responses to Two Sequential Protease Inhibitor Regimens in Saquinavir and Reverse Transcriptase Inhibitor–Experienced PersonsThe Journal of Infectious Diseases, 1999
- Impact of drug resistance mutations on virologic response to salvage therapyAIDS, 1999
- Activities of cefepime and five other antibiotics against nosocomial PER-1-type and/or OXA-10-type beta-lactamase-producing Pseudomonas aeruginosa and Acinetobacter spp.Journal of Antimicrobial Chemotherapy, 1998
- Report of the NIH Panel To Define Principles of Therapy of HIV Infection*Annals of Internal Medicine, 1998
- Drug resistance and virologic response in NUCA 3001, a randomized trial of lamivudine (3TC) versus zidovudine (ZDV) versus ZDV plus 3TC in previously untreated patientsAIDS, 1996